BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This ...
Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 ...
Immunoglobulin—one of nature's own defence mechanisms—is a highly effective treatment for a wide variety of inflammatory diseases, and has become an important but expensive weapon in the neurologist's ...
Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results